In vivo Reprogramming of Adult Somatic Cells to Pluripotency by Overexpression of Yamanaka Factors
December 17th, 2013
This study demonstrates the reprogramming of somatic cells towards pluripotency in vivo without the generation of teratomas. We used hydrodynamic tail vein injection of plasmid DNA encoding the Yamanka factors to induce the in vivo reprogramming of adult hepatocytes into cells of enhanced pluripotency.
Overview
This study demonstrates the reprogramming of somatic cells towards pluripotency in vivo without the generation of teratomas. The method involves hydrodynamic tail vein injection of plasmid DNA encoding the Yamanaka factors to induce the reprogramming of adult hepatocytes.
Key Study Components
Area of Science
- Cell Reprogramming
- Pluripotency
- Hepatocyte Biology
Background
- Reprogramming somatic cells can provide insights into cellular plasticity.
- Yamanaka factors are known to induce pluripotency in somatic cells.
- In vivo reprogramming may offer advantages over in vitro methods.
- Understanding the safety and efficiency of this approach is crucial.
Purpose of Study
- To assess the reprogramming of somatic cells towards pluripotency in vivo.
- To evaluate the safety and efficiency of the hydrodynamic injection method.
- To analyze gene and protein expression changes in reprogrammed cells.
Methods Used
- Hydrodynamic tail vein injection of plasmid DNA encoding Yamanaka factors.
- Isolation of primary hepatocytes from liver tissues.
- Real-time Q-R-T-P-C-R and flow cytometry for gene and protein expression analysis.
- Histological techniques to confirm reprogramming and assess toxicity.
Main Results
- Successful reprogramming of adult hepatocytes into cells with enhanced pluripotency.
- Significant differences in gene and protein expression of pluripotency markers.
- Validation of the safety of the approach through biochemical and histological evidence.
- Fast and efficient reprogramming observed in vivo.
Conclusions
- The study provides a novel method for in vivo reprogramming of somatic cells.
- This approach may advance research in cellular reprogramming and regenerative medicine.
- Further studies are needed to explore the long-term effects and applications of this technique.
Frequently Asked Questions
Executive Industry Relevance
In vivo reprogramming of somatic cells to pluripotency offers a rapid, efficient, and transient approach to generate pluripotent cells without teratoma formation, addressing key safety and efficiency barriers in regenerative medicine. This method enables direct tissue-specific reprogramming, reducing reliance on lengthy in vitro differentiation and associated genomic instability risks. It supports early-stage target validation by providing a disease-relevant system for mechanistic de-risking of pluripotency-based therapies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by inducing pluripotency in native tissue microenvironments.
- Operational Value: Provides a rapid, high-efficiency system for functional target validation with fast kinetics.
- Predictive Value: Supports predictive confidence through transient, controlled reprogramming without tumorigenic outcomes.
Screening & Assay Development
- Scientific Value: Generates validated biological systems with quantifiable pluripotency and hepatocyte marker dynamics for assay standardization.
- Operational Value: Delivers reproducible, scalable readouts via Q-RT-PCR and flow cytometry for compound screening readiness.
- Translational Value: Produces disease-relevant hepatocytes with transient pluripotency for preclinical model development.
Translational & Preclinical Research
- Scientific Value: Demonstrates continuity from somatic cell reprogramming to pluripotency marker expression in vivo.
- Operational Value: Enables risk-adjusted advancement decisions through validated safety profiles (no teratoma, normal liver function).
- Predictive Value: Supports mechanistic de-risking by confirming transient tissue changes and baseline recovery.
Pipeline & Workflow Integration
The method integrates into early discovery for target validation, feeds screening via standardized hepatocyte-derived pluripotent systems, and informs preclinical work through safety-validated, transient reprogramming outputs.
- Discovery Biology: Supports hypothesis testing via in vivo induction of pluripotency and pathway clarification in hepatocytes.
- Screening: Enables assay readiness through reproducible isolation and quantification of reprogrammed primary hepatocytes.
- Analytics: Delivers quantitative gene and protein expression measurements (OKSM, Nanog, Rex1, hepatocyte markers) for condition comparison.
- Translational Research: Connects to preclinical continuity via validated safety and transient phenotype in liver tissue.
- Enterprise Reuse: Establishes a reusable platform for tissue-specific in vivo reprogramming using adaptable gene delivery vectors.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in pluripotency induction, reduction of mechanistic ambiguity in reprogramming trajectories.
- Operational Value: Standardization via hydrodynamic injection, reproducible Q-RT-PCR and flow cytometry workflows.
- Strategic Value: Better go/no-go decisions through rapid, safe, and efficient reprogramming without tumorigenic risk.
- Portfolio Impact: Risk-adjusted prioritization based on transient efficacy and safety validation in vivo.
Implementation Considerations
- Requires expertise in molecular biology, viral/nonviral vector design, and primary hepatocyte isolation.
- Needs hydrodynamic injection capability, Q-RT-PCR, flow cytometry, and histological imaging infrastructure.
- Demands cross-team standardization for vector dosing, timing, and tissue-specific promoter selection.
- Requires adaptation considerations for non-hepatic tissues via tailored gene delivery systems.
- Practical limitations include transient expression duration and tissue-specific vector efficiency, as noted in the study.
Biopharma FAQs
Chapters in this video
0:05
Title
1:34
In vivo Reprogramming and Isolation of Liver Tissue
3:40
RNA and Flow Cytometry Analysis of Enhanced Pluripotency
5:34
Immunostaining of Liver Sections for Markers of Pluripotency
6:57
Alkaline Phosphatase Staining of Liver Tissue Sections
7:47
Assessment of Liver Toxicity
9:00
Results: Reprogramming of Somatic Cells Following Hydrodynamic Tail-vein Injection of OKSM Factors
11:24
Conclusion
